$4.21
-0.09 (-2.09%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where XFOR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
11 interventional · 1 observational · 3 with posted results
Held by 6 tracked-famous managers (Squarepoint Ops LLC, Point72 Asset Management, L.P., TWO SIGMA INVESTMENTS, LP, RENAISSANCE TECHNOLOGIES LLC, WINTON GROUP Ltd, +1 more) · FINRA short interest 12.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious InfectionsNCT06056297Co-primary Endpoint: Annualized Infection Rate Based on Infections Adjudicated by Blinded Infection Adjudication Committee (BIAC) During the Treatment PeriodRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Mavorixafor, Placebo | Neutropenia | 176 | Sep 2027 | ≤ 407 d | 2026-08-06 |
| A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic FunctionNCT06858696Maximum Observed Plasma Concentration (Cmax) of MavorixaforNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Mavorixafor | Hepatic Insufficiency | 39 | 2026-01-12actual | — | 2026-07-15 |
| Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) SyndromeNCT03995108Randomized Placebo-Controlled Period: Time (in Hours) Above Threshold-Absolute Neutrophil Count (TAT-ANC in hours) of ≥ 500 Cells/Microliter (µL) over a 24-hour periodRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Mavorixafor, Placebo | WHIM Syndrome | 31 | 2025-12-23actual | — | 2026-07-06 |
| Drug-Drug Interaction Potential of MavorixaforNCT06914869Cohort 1: Maximum Observed Plasma Concentration (Cmax) of Mavorixafor Without (Day 1) and With (Day 18) Coadministration With CarbamazepineRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Mavorixafor, Carbamazepine, Efavirenz | Healthy Participants | 38 | 2025-05-19actual | — | 2025-07-01 |
| A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia DisordersNCT04154488Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of MavorixaforOpen-label · Treatment | Phase 1/2 | Completed | Drug: Mavorixafor | Neutropenia | 32 | 2024-08-27actual | — | 2025-08-06 |
| A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4NCT04274738Number of Participants With DLTsOpen-label · Treatment | Phase 1 | Completed | Drug: Mavorixafor, Ibrutinib | Waldenstrom's Macroglobulinemia | 16 | 2022-10-31actual | — | 2024-08-27 |
| A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) SyndromeNCT03005327results2024-10-30Mean Value of the Area Under the Plasma Concentration-time Curve for Absolute Neutrophil Count (AUCANC)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: X4P-001 | WHIM Syndrome | 8 | 2022-06-16actual | — | 2024-10-30 |
| Trial of X4P-001 in Participants With Advanced Renal Cell CarcinomaNCT02667886results2024-08-14Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: X4P-001, axitinib | Clear Cell Renal Cell Carcinoma | 74 | 2022-04-14actual | — | 2024-10-03 |
| A Retrospective and Prospective Natural History Study of Patients With WHIM SyndromeNCT03087370observationalIncidence of infections | — | Withdrawnsponsor's stated reason: Company Decision | Other: No intervention | WHIM Syndrome | 0 | Mar 2022 | — | 2018-12-07 |
| Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell CarcinomaNCT02923531results2022-12-29Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Due to low enrollment, the study was terminated early. | Drug: X4P-001, Nivolumab | Clear Cell Renal Cell Carcinoma | 9 | 2018-08-08actual | — | 2022-12-29 |
| X4P-001 and Pembrolizumab in Patients With Advanced MelanomaNCT02823405Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)Open-label · Treatment | Phase 1 | Completed | Drug: X4P-001, Pembrolizumab | Melanoma | 16 | 2018-03-15actual | — | 2020-07-07 |
| A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy VolunteersNCT02680782Incidence of treatment emergent adverse events (safety and tolerability) in subjects administered X4P-001 200 mg twice daily compared with 400 mg once daily.Randomized · Open-label · Treatment | Phase 1 | Terminated | Drug: X4P-001 | Healthy | 15 | 2016-02-28actual | — | 2018-12-07 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19